Nexalin Technology awarded U.S. patent related to TACS system
The Fly

Nexalin Technology awarded U.S. patent related to TACS system

Nexalin Technology announced that the United States Patent and Trademark Office, USPTO, has awarded U.S. Patent No. 11,872,397 relating to the Company’s non-invasive, frequency-based deep brain stimulation device. The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation, TACS, System,” covers the core technology utilized in the Company’s Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner. Mark White, CEO of Nexalin Technology, stated, “This patent award for our non-invasive, deep-frequency stimulation device marks a major milestone for the Company, as it extends our IP protection through 2040. Most notably, the unique nature of our device’s waveform can only be created with very specific electrical components, capacitors and designs. This patent covers these three key areas, and we believe it further protects the Company from others trying to circumvent our IP. Importantly, this patent marks what we believe is a major advancement for the drug-free treatment of mental health conditions. Recent published clinical evidence supports the clinical benefits of the Nexalin device for the treatment of a variety of neurological diseases associated with deep brain structures. At Nexalin, we are highly encouraged that our DIFS technique will improve mental healthcare outcomes among patients. Specifically, clinical studies have demonstrated therapeutic benefits in conditions ranging from treatment-resistant depression to migraines, anxiety, and insomnia. We are also targeting mental health conditions such as addiction, substance use disorder, Alzheimer’s, traumatic brain injury and PTSD. According to Allied Market Research, the global mental health market was an estimated $383 billion in 2020 and is projected to reach $537 billion by 2030. We believe our neurostimulation device has the potential to transform the standard of care for the treatment of mental health disorders. We are laser-focused on advancing the commercial rollout, including expanding our regulatory approvals in overseas markets, as well as pursuing regulatory clearance in the U.S.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NXL:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App